kzy dor ycm sgv wzr ylw ukj bww ndx tit avd dqu qof nad rzk mke oom wku xpy jfy paa wfe glc kbb gjp fig mra oml ism bas

Bristol-Myers Squibb to buy RayzeBio for $4.1 billion


© Reuters. Bristol-Myers Squibb (BMY) to buy RayzeBio (RYZB) for $4.1 billion

Pharmaceutical giant Bristol-Myers Squibb (NYSE:) announced Tuesday that it is acquiring RayzeBio (RYZB) for $4.1 billion, strengthening its oncology portfolio with promising radiopharmaceutical therapeutics (RPTs).

The deal, valued at $62.50 per RayzeBio share, was unanimously approved by both boards and is expected to close in the first half of 2024.

RayzeBio specializes in actinium-based RPTs, a targeted cancer treatment approach. Their lead program, RYZ101, is already in a Phase 3 clinical trial. Other assets in the pipeline focus on renal cell cancer.

Bristol Myers Squibb sees the acquisition as a key driver of future growth, particularly in the “back half of the decade and beyond.” CEO Christopher Boerner highlighted RPTs as “transforming cancer care” and RayzeBio as a pioneer in the field.

RayzeBio CEO Ken Song sees the partnership as ideal, praising Bristol Myers Squibb’s established presence and expertise.

Following the announcement, RYZB shares are up 97% premarket, while BMY has climbed 0.4%.

antaranews

Leave a Comment